Cellular Therapy with Mesenchymal Stromal Cells in Sepsis

link.springer.com January 28, 2025

Cellular therapy with mesenchymal stromal cells (MSCs) is a promising therapeutic modality in sepsis. Positive effects are mainly associated with frequent infusions and the dose of 1 × 106 cell/kg. Larger scale studies are needed to address the pending questions about the optimal indications and cell manipulation conditions.

We gathered available evidence in a meta-analysis to figure out if clinical advantage of cellular therapy in sepsis. Eleven trials were included with total of 360 patients, 191 received MSCs and 169 as control.

The overall mortality was 0.248 with 95% CI 0.191–0.316. Relative to control, mortality Odds ratio (OR) was 0.54, 95% CI 0.294–1.006 and P = 0.05. Frequent MSCs infusions showed better survival, OR = 0.3, 95% CI 0.1–0.87 and P = 0.03.

While survival in the cohort that received infrequent MSCs infusions was comparable with the control, OR = 0.7, 95% CI 0.35–1.41 and P = 0.3.